Bricasma Tablet

1:09 AM
Bricasma® tablet
terbutaline sulphate
Selective bronchodilator


Composition
Each tablet contain Terbutaline Sulphate 2.5 mg

Characteristics
Bricasma is a sympathomimetic bronchodilator with a degree of selective B2 stimulant activity on the respiratory system.
Bricasma increases impaired mucocillary clearance in obstructive lung diseases and improves the transport of sticky mucous. The outstanding characteristics in all presentation is its long duration of action. Contary to the long known sympathomimetic amines that affect also the B1 receptors in the heart with consequent palpitation and discomforts for the patient. Therapeutic doses of Bricasma very seldom produce these effects.

Indication
For the release of bronchospasm in bronchial asthma, chronic bronchitis, emphysema and other diseases of the lung, where bronchoconstriction is a complicating factor.

Contraindications
Patients with a history of hypersensitivity to any of its component or sympathomimetic amines.
Patients with thyrotoxicosis should use Bricasma with caution.

Side effects
The frequency of side effects with oral bricasma is low.
Those recorded, e.g. tremor, and palpitations, are characteristic of symphatomimetic amines. In patients will disappear after a few days of treatment and if palpitation occur, these will subside if the dose is lowered.
Other commonly reported reactions include increased heart rate and dizziness.
Other reported reactions include headache, drowsiness vomiting, nausea, sweating, and muscle cramps. These reactions are generally transient and usually do not require treatment. There have been rare reports of elevations in liver enzymes and of hypersensitivity vasculitis.

Dosage for adults
1 - 2 tablets, 2-3 times a day. In most patients the optimum single dose is 2 tablets. In patients being unusually sensitive to symphathomimetic amines, it is advisable to initiate treatment with 1 tablet 2-3 times a day.

A total dose of 15 mg in a 24 hour period should not be exceeded

Dosage for children
7-15 years : 25 mg, 2 - 3 times daily.

Precaution
Bricasma should not be given together with non-selective beta-blocker.
Terbutaline is not indicated and should not be used for the management of preterm labor. Serious adverse reactions have been reported following administration of Terbutaline sulfate to women in labor.
These reports have included transient hypokalemia, pulmonary edema ( sometimes after delivery ), and hypoglycemia in the mother and / or neonatal child. Maternal death has been reported with terbutaline sulfate and other drugs of this class.
There have been rare reports of seizures occuring in patients receiving terbutaline, which do not recur when the drug is discontinued and have not been explained on any other basis.
Terbutaline sulphate is a sympathomimetic amine and such should be used with caution in patients with cardiovascular disorders ( including arrythmias, coronary insufficiency and hypertension), in patients with hyperthyroidism or diabetes mellitus, history of seizures, or in patients who are unusually responsive to sympathomimetic amines.
Patients susceptible to hypokalemia should be monitored because transient early alls in serum potassium levels have been reported with β agonists. Immediate hypersensitivity reactions and exacerbation of bronchospasm have been reported after terbutaline administration.
There are, however, no adequate and well - controlled studies in pregnant women, this drug should be used during pregnancy only if clearly needed.
Terbutaline is excreted in breast milk. Caution should be exercised when this drug is administered to a nursing woman.
Safety and effectiveness in children below the age of 12 have not been established.

OVERDOSAGE
Too frequent administration, as with other sympathomimetic agents, may cause nausea, headaches, changes in blood pressure, anxiety, tension, insomnia, tremor. The symptoms and sign are those characteristic of excessive symphatetic stimulation.

Storage
Store below 30°C, protect from tight and moisture

Presentation
Box of 10 x 10 tablets in strips

HARUS DENGAN RESEP DOKTER
Reg. No.: DKL0008902610A1

Manufactured by:
PT AstraZeneca Indonesia
Jl. Raya Kasri 153, Pandaan, Jawa Timur

Trade Marks herein are the property of the AstraZeneca group

Share this :

Previous
Next Post »
0 Komentar

Penulisan markup di komentar
  • Silakan tinggalkan komentar sesuai topik. Komentar yang menyertakan link aktif, iklan, atau sejenisnya akan dihapus.
  • Untuk menyisipkan kode gunakan <i rel="code"> kode yang akan disisipkan </i>
  • Untuk menyisipkan kode panjang gunakan <i rel="pre"> kode yang akan disisipkan </i>
  • Untuk menyisipkan quote gunakan <i rel="quote"> catatan anda </i>
  • Untuk menyisipkan gambar gunakan <i rel="image"> URL gambar </i>
  • Untuk menyisipkan video gunakan [iframe] URL embed video [/iframe]
  • Kemudian parse kode tersebut pada kotak di bawah ini
  • © 2015 Simple SEO ✔